Price Chart

Price Chart

Profile

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
URL http://www.oncternal.com
Investor Relations URL N/A
HQ State/Province California
Sector  
Industry  
Equity Style N/A
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
URL http://www.oncternal.com
Investor Relations URL N/A
HQ State/Province California
Sector  
Industry  
Equity Style N/A
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A